AI News

Samsung’s chip workers are jumping ship to rival SK Hynix 

Lee, an engineer at Samsung’s semiconductor division, clocks out when his shift ends. He used to work longer hours, going the extra mile to excel at his projects. But lately, he’s been coming straight home to work on his job application for the chipmaker’s South Korean rival SK Hynix, sharing tips with his coworkers on…

Read More »

Armenia’s AI Bet Is Not Chip Manufacturing. It Is Compute Sovereignty 

Armenia is not a big country. It’s not a wealthy country. It’s not a famous country. And yet, it has become not only a consumer of different AI products akin to Clideo subtitles generator for video editing, or giants like OpenAI, but also entered the headlines of global news for several reasons, not the least […]

The post Armenia’s AI Bet Is Not Chip Manufacturing. It Is Compute Sovereignty  appeared first on AI News.

Read More »

Microsoft AI Releases MAI-Cyber-1-Flash: A 5B-Active-Parameter Cyber Model That Pushes MDASH to 95.95% on CyberGym

Microsoft AI has released MAI-Cyber-1-Flash, its first model built specifically for cyber defense. It is a 137B total, 5B active sparse MoE fine-tune of MAI-Code-1-Flash with a 256k context window. The model does not ship as a standalone endpoint — it runs inside MDASH, Microsoft’s multi-model agentic scanning harness, where it handles up to 90% of tasks and pushes the system to 95.95% on CyberGym.

The post Microsoft AI Releases MAI-Cyber-1-Flash: A 5B-Active-Parameter Cyber Model That Pushes MDASH to 95.95% on CyberGym appeared first on MarkTechPost.

Read More »

Why China is giving away its best AI models

Silicon Valley has spent much of the past week on red alert, digesting the arrival of Moonshot AI’s Kimi K3, a Chinese AI model that can allegedly beat some of the best systems built by US companies at a fraction of the cost. Its performance alone would have been enough to intensify the rivalry between […]

Read More »

Building the enterprise environment for agentic AI

For the enterprise, the promise of agentic AI is much more than just a better chatbot. It is software agents that execute business tasks end-to-end across people, business workflows, data, and systems. The platform best-suited to run agents is built with proper CPU capacity, resilient data access, policy-aware tool use, observability, memory management, and the…

Read More »

Closing the data loop in AI-driven drug discovery

Drug discovery is a high-cost, high-risk endeavor that is under growing pressure from a market increasingly defined by first-mover advantage. Since the 1950s, the cost of developing new pharmaceuticals has roughly doubled every nine years—a phenomenon known as Eroom’s Law. Today, bringing a new drug to market takes an average of 10-15 years and costs…

Read More »

The path to artificial superintelligence

Imagine a healthcare system made up of multiple AI agents: one that manages symptom assessment, another scheduling, a third insurance, and a fourth pharmacy. Each is an expert in its domain. But they all have their own distinct knowledge and objectives. Today they can exchange data, but they are not yet able to actually coordinate…

Read More »

America’s AI Investment Boom Is Reshaping the Economy

America’s AI Investment Boom Is Reshaping the Economy Artificial intelligence has become one of the defining investment stories in the United States, and the numbers continue to grow. Microsoft, Meta, Amazon and Alphabet are collectively committing hundreds of billions of dollars to AI infrastructure, while demand for advanced chips has turned NVIDIA into one of […]

The post America’s AI Investment Boom Is Reshaping the Economy appeared first on AI News.

Read More »

How AI is shortening drug discovery timelines in China

Insilico Medicine has reduced the time needed to produce some drug development candidates to about one year by combining artificial intelligence with laboratory research in China, according to CEO Alex Zhavoronkov. The Hong Kong-listed company’s fastest programme reached candidate nomination in nine months, while its typical timeline is about 13 months, Zhavoronkov said. He said […]

The post How AI is shortening drug discovery timelines in China appeared first on AI News.

Read More »